(426 days)
Not Found
No
The device description focuses on the physical process of laser generation and delivery, with no mention of AI or ML for image analysis, treatment planning, or any other function.
Yes
The device is indicated for use in photocoagulation of various abnormalities of the retina and choroid, as well as for treatments for glaucoma and other laser treatments, which are therapeutic interventions.
No
The device description and intended use indicate that the NGL is a laser used for photocoagulation and other laser treatments of the eye; it is a therapeutic device, not a diagnostic one.
No
The device description clearly outlines hardware components, including a diode pumped Neodymium-doped solid state laser, a laser diode aiming beam, a footswitch for actuation, and accessories like a slit lamp, laser probe, or LIO for delivery. This is not a software-only device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used outside of the body.
- Device Function: The NGL Ophthalmic Laser is a device that delivers a laser beam directly to the eye for therapeutic purposes (photocoagulation, iridotomy, trabeculoplasty, etc.). It is used on the patient's body, not on a sample taken from the body.
- Intended Use: The intended use clearly describes treatment procedures performed on the eye, not diagnostic testing of biological samples.
Therefore, the NGL Ophthalmic Laser is a therapeutic medical device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The NGL is indicated for use in photocoagulation of both anterior and posterior segments of the eye including:
- Retinal Photocoagulation, panretinal photocoagulation and intravitreal. endophotocoagulation of vascular and structural abnormalities of the retina and choroid including:
- Proliferative and nonproliferative retinopathy (including diabetic);
- Choroidal neovascularization secondary to age-related macular degeneration;
- Retinal tears and detachments;
- Macular Edema;
- Retinopathy of prematurity;
- Choroidal neovascularization;
- Leaking microaneurysms.
- Iridotomy/Iridectomy for treatment of Chronic/Primary Open Angle Glaucoma . (COAG,POAG), Acute Angle Closure Glaucoma (AACG), and Refractory Glaucoma.
- Trabeculoplasty for treatment of Chronic/Primary Open Angle Glaucoma . (COAG,POAG) and Refractory Glaucoma.
- And other laser treatments including: .
- Internal sclerostomy;
- Lattice degeneration;
- Central and Branch Retinal Vein Occlusion;
- Suturelysis;
- Vascular and pigmented skin lesions.
Product codes
HQF
Device Description
The NGL Ophthalmic Laser, like its predicate device Alcon Ophthalas® 532 EyeLite® (EyeLite®), is a diode pumped Neodymium-doped solid state laser designed for ophthalmic use. LASER is an acronym for "Light Amplification by Stimulated Emission of Radiation." This laser delivers a visible 532 nm green laser beam (frequency doubled), and a visible 635 mm Diode Laser aiming beam (635 nm is an approximate value between 630-640 nm). The laser firing is actuated by footswitch. The laser is delivered to the patient through any of the following accessories (a) Slit Lamp, (b) Laser Probe or (c) Laser Indirect Ophthalmoscope (LIO). In case of the NGL, like its predicate device Alcon Ophthalas® 532 EyeLite®, the laser beam is generated when a laser diode beam excites the Neodymium atoms in the rod material. When one atom which has been excited by the beam returns to its initial stable level, the energy difference between the two states is emitted as radiation in the form of a photon. When this photon meets another excited atom, emission of a second photon occurs. The second photon has the same phase, wavelength, and direction as the first photon. The light emitted in this manner oscillates between two end mirrors. The light is amplified by this stimulated emission process and a laser beam is produced. This laser beam is frequency doubled in a special crystal. The crystal is an optical dielectric that exhibits a non-linear optical response. The 532 nm wavelength is produced by harmonic generation. These steps leading to generation of the output laser beam generation is done in the laser engine module of the device. A red 635 nm laser diode provides the visible aiming beam in NGL.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
anterior and posterior segments of the eye
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.4390 Ophthalmic laser.
(a)
Identification. An ophthalmic laser is an AC-powered device intended to coagulate or cut tissue of the eye, orbit, or surrounding skin by a laser beam.(b)
Classification. Class II.
0
5. 510(K) SUMMARY
This summary is in accordance with 21 CFR 807.92(c).
KO 62624
The submitter of the 510(k) is:
Terry J. Dagnon . Director, Regulatory Affairs Alcon, Inc. 6201 South Freeway Fort Worth, Texas 76134 Phone: (817) 551-4325 Fax: (817) 551-4630
NOV -- 5 2007
Date Prepared: August 31, 2006
Device Subject to this 510(k):
Next Generation Laser Trade Name: Common Name: Ophthalmic Laser or, Frequency Doubled (532nm) Laser Classification Name: Laser, Ophthalmic (21 CFR 886.4390)
5.1. Predicate Devices
510(k) Number Device
| K962592 | Alcon Eyelite® |
|---|---|
| K041598 | Laserex™ Solitaire |
| K031665 | Iris Medical Oculight™ |
5.2. Device Description
The NGL Ophthalmic Laser, like its predicate device Alcon Ophthalas® 532 EyeLite® (EyeLite®), is a diode pumped Neodymium-doped solid state laser designed for ophthalmic use. LASER is an acronym for "Light Amplification by Stimulated Emission of Radiation." This laser delivers a visible 532 nm green laser beam (frequency doubled), and a visible 635 mm Diode Laser aiming beam (635 nm is an approximate value between 630-640 nm).
The laser firing is actuated by footswitch. The laser is delivered to the patient through any of the following accessories (a) Slit Lamp, (b) Laser Probe or (c) Laser Indirect Ophthalmoscope (LIO).
In case of the NGL, like its predicate device Alcon Ophthalas® 532 EyeLite®, the laser beam is generated when a laser diode beam excites the Neodymium atoms in the rod material. When one atom which has been excited by the beam returns to its initial stable level, the energy difference between the two states is emitted as radiation in the form of a photon. When this photon meets another excited atom, emission of a second photon occurs. The second photon has the same phase, wavelength, and direction as the first photon. The light emitted in this manner oscillates between two end mirrors. The light is amplified by this
1
stimulated emission process and a laser beam is produced. This laser beam is frequency doubled in a special crystal. The crystal is an optical dielectric that exhibits a non-linear optical response. The 532 nm wavelength is produced by harmonic generation. These steps leading to generation of the output laser beam generation is done in the laser engine module of the device.
A red 635 nm laser diode provides the visible aiming beam in NGL.
5.3. Indications for Use
The NGL is indicated for use in photocoagulation of both anterior and posterior segments of the eye including:
- Retinal Photocoagulation, panretinal photocoagulation and intravitreal . endophotocoagulation of vascular and structural abnormalities of the retina and choroid including:
- Proliferative and nonproliferative retinopathy (including diabetic); ।
- Choroidal neovascularization secondary to age-related macular degeneration; -
- Retinal tears and detachments; -
- Macular Edema; -
- Retinopathy of prematurity; -
- Choroidal neovascularization; -
- Leaking microaneurysms. -
- Iridotomy/Iridectomy for treatment of Chronic/Primary Open Angle Glaucoma . (COAG,POAG), Acute Angle Closure Glaucoma (AACG), and Refractory Glaucoma.
- Trabeculoplasty for treatment of Chronic/Primary Open Angle Glaucoma . (COAG,POAG) and Refractory Glaucoma.
- And other laser treatments including: .
- Internal sclerostomy; -
- Lattice degeneration; -
- Central and Branch Retinal Vein Occlusion; -
- -Suturelysis;
- Vascular and pigmented skin lesions. -
5.4. Brief Summary of Nonclinical Tests and Results
The device will comply with applicable sections of 21 CFR 1040 and the following standards:
| Standard # | Title |
|---|---|
| 11135 AAMI/ISO | Medical Devices – Validation and Routine Control of Ethylene |
| Oxide Sterilization | |
| 14971 ISO | Medical Devices: Application of Risk Management to Medical |
| Devices | |
| 10993-1 AAMI / | |
| ANSI / ISO | Biological evaluation of medical devices -- Part 1: Evaluation and |
| testing | |
| 10993-5 AAMI / | Biological evaluation of medical devices -- Part 5: Tests for In Vitro |
2
| Standard # | Title |
|---|---|
| ANSI / ISO | cytotoxicity |
| 10993-7 AAMI / | |
| ANSI / ISO | Biological Evaluation of Medical Devices - Part 7: Ethylene Oxide |
| Sterilization Residuals | |
| 10993-10 AAMI / | |
| ANSI / ISO | Biological evaluation of medical devices -- Part 10: Tests for |
| irritation and sensitization | |
| 10993-11 AAMI / | |
| ANSI / ISO | Biological Evaluation of Medical Devices - Part 11: Tests for |
| systemic toxicity | |
| EN 60601-1: 1990 | Medical Electrical Equipment, Part 1 - General Requirements for |
| Safety. (Including A1:1992, A2:1995 and A13:1995) | |
| EN 60601-1-2: 2001 | Medical electrical equipment Part 1: General requirements for safety |
- Collateral Standard: Electromagnetic compatibility-Requirements
and test. |
| EN 60601-2-22: 1996 | Medical electrical equipment Part 2: Particular requirements for the
safety of diagnostic and therapeutic laser equipment |
| EN 60601-1-4:1996 | Medical Electrical Equipment, Part 1: General Requirements for
Safety. 4. Collateral standard: Programmable electrical medical
systems. (Including A1: 1999) |
| UL 60601-1: 2003 | Medical Electrical Equipment, Part 1 - General Requirements for
Safety |
| IEC 60825-1:1993 | Radiation safety of laser products, equipment classification,
requirements and user's guide. (Including A1:1997 and A2:2001) |
Technological characteristics affecting clinical performance are similar to that of predicate devices previously listed. The Next Generation Laser system will be developed and manufactured in compliance with FDA and ISO quality system requirements. Testing will demonstrate that the functional requirements have been met and that the system specifications have been met prior to commercial product release.
The NGL console is provided non-sterile, and is not intended to be sterilized.
The Laser Probes are provided sterile. They are intended for single use.
Sterilization method for the Laser Probes will be a validated EtO sterilization cycle.
The Laser Probes will utilize the same packaging concept as used previously for similar products of adhesive backed Tyvek lidding sealed to HIPS (high impact polystyrene) trays. These packs can withstand validated sterilization processes of EtO sterilization to achieve a 10 6 SAL (sterility assurance level).
5.5. Trademark Reference
Oculight is a registered trademark of Iris Medical Laserex is a registered trademark of Ellex Medical Pty. Ltd.
3
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Alcon Research, Ltd. % Terry J. Dagnon Director, Regulatory Affairs 6201 South Freeway Fort Worth, Texas 76134
NOV - 5 2007
Re: K062624
Trade/Device Name: Next Generation Laser Regulation Number: 21 CFR 886.4390 Regulation Name: Opthalmic laser Regulatory Class: II Product Code: HQF Dated: August 15, 2007 Received: August 16, 2007
Dear Terry Dagnon:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 - Terry J. Dagnon
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely ve
follon Dr
Mark N. Melkerson
Director
Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
4. INDICATIONS AND USE STATEMENT
Page 1 of 1
510(k) Number (if known): K062624
Device Name: Next Generation Laser
Indications for Use:
The NGL is indicated for use in photocoagulation of both anterior and posterior segments of the eye including:
- Retinal Photocoagulation, panretinal photocoagulation and intravitreal . endophotocoagulation of vascular and structural abnormalities of the retina and choroid including:
- Proliferative and nonproliferative retinopathy (including diabetic); ।
- I romeral re and many to age-related macular to age-related macular degeneration; ー
- Retinal tears and detachments; -
- Macular Edema; -
- Retinopathy of prematurity; -
- Choroidal neovascularization; -
- Leaking microaneurysms.
- Iridotomy/Iridectomy for treatment of Chronic/Primary Open Angle Glaucoma . (COAG,POAG), Acute Angle Closure Glaucoma (AACG), and Refractory Glaucoma.
- Trabeculoplasty for treatment of Chronic/Primary Open Angle Glaucoma . (COAG,POAG) and Refractory Glaucoma.
- And other laser treatments including: .
- Internal sclerostomy; -
- Lattice degeneration; -
- Central and Branch Retinal Vein Occlusion; -
- Suturelysis; -
- Vascular and pigmented skin lesions. -
| Prescription Use
(Part 21 CFR 801 Subpart D) | X | AND/OR | Over-The-Counter Use
(21 CFR 801 Subpart C) |
| ------------------------------------------------- | ---------- | -------- | ------------------------------------------------ |
|---|
(PLEASE DO NOT WRITE BELOW THIS LINE CONTINUE ON ANOTHER PAGE IF NEEDED)
(Division Sign Off)
Division of General, Restorative,
Concurrence of CDRH, Office of Device Evaluation (ODE)
and Neurological Devices
| 510(k) Number | 11062624 |
|---|---|
| --------------- | ---------- |